arrow_back Back to App

Accelerating Pediatric Cancer Drug Research: New FDA Rules and Incentives Extended.

This Act aims to accelerate the investigation of new molecularly targeted cancer drugs for children. It mandates pharmaceutical companies to study their adult cancer drugs for pediatric use if the molecular target is relevant to childhood cancers. Furthermore, it extends the Priority Review Voucher program until 2029, which incentivizes companies to develop treatments for rare pediatric diseases, potentially increasing the availability of life-saving therapies for young patients.
Key points
Mandatory Pediatric Investigations: Companies developing new adult cancer drugs must conduct molecularly targeted pediatric cancer investigations if the drug's target is relevant to childhood cancers.
Faster Drug Access for Children: The changes are designed to speed up the testing and approval of oncology drugs for children, potentially leading to better treatment outcomes.
Extension of Financial Incentives: The Priority Review Voucher program for rare pediatric disease drugs is extended until September 2029, encouraging industry investment in these critical therapies.
Accountability and Review: The government will conduct studies to assess the effectiveness of these new rules and incentives in actually developing drugs for pediatric cancer and rare diseases.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_932
Sponsor: Sen. Mullin, Markwayne [R-OK]
Process start date: 2025-03-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Give Kids a Chance Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_932.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-03-11.

What are the main provisions?

Key points include:

  • Mandatory Pediatric Investigations: Companies developing new adult cancer drugs must conduct molecularly targeted pediatric cancer investigations if the drug's target is relevant to childhood cancers.
  • Faster Drug Access for Children: The changes are designed to speed up the testing and approval of oncology drugs for children, potentially leading to better treatment outcomes.
  • Extension of Financial Incentives: The Priority Review Voucher program for rare pediatric disease drugs is extended until September 2029, encouraging industry investment in these critical therapies.
  • Accountability and Review: The government will conduct studies to assess the effectiveness of these new rules and incentives in actually developing drugs for pediatric cancer and rare diseases.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Mullin, Markwayne [R-OK].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health